Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Govt Approves 1st Use Of Regenerative Medicine In Japan (Japan)

This article was originally published in PharmAsia News

Executive Summary

The Japanese government has given approval to Bioventure Japan Tissue Engineering Co. (J-TEC) to manufacture and sell skin for use in treating serious burns, the first such approval for the use of regenerative medicine in Japan. Skin cells that have been cultured for approximately two weeks are used in the treatment, with technology enabling a 1-sq.-cm sample to grow up to 1,000 times larger. The new skin, once grown, is applied to the damaged part of the body, significantly reducing the chances of rejection compared with procedures using another person's skin. J-TEC also plans to seek approval from the Health Ministry for regenerative treatments to restore the functions of knee cartilage and the epithelium of the cornea. (Click here for more - May Require Paid Subscription

You may also be interested in...



Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.

Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.

US FDA Launches Quality Maturity Pilots That Reward High-Performing OTC, Rx Manufacturers

One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel